Who are Eledon's investors?

Eledon's investors include JDRF T1D Fund, Biotechnology Value Fund, Newpath Partners.

Eledon

3 known investors

Find your way into Eledon

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.

AI & Machine Learning Biotech Medical Devices

Founders & leadership

Steven PerrinPresident and Chief Scientific Officer

Investors · 3

JDRF T1D Fundlisted by JDRF T1D FundBoston

Biotechnology Value FundreportedSan Francisco

How we know: globalgenes.org · Not right? Tell us

Newpath PartnersreportedBoston · $50K – $10M

How we know: the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountprivate investment in public equity financingMay 2024
BVF Partners (lead)
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 | Eledon Pharmaceuticals, Inc.ir.eledon.com · Sep 2026

Frequently asked questions

What does Eledon do?: Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
Who are Eledon's investors?: Eledon's investors include JDRF T1D Fund, Biotechnology Value Fund, Newpath Partners.